Theraclion Delivers a Structuring Year in 2025 and Prepares to Scale up

About this update from Theraclion Sa

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2277,"height":853,"url":"https://media.zenfs.com/en/business-wire.com/3877a14729dc5f1fce3a3e099213b3e8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6BKV5RGw7VcrBH07TAmddw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM2MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/3877a14729dc5f1fce3a3e099213b3e8","width":960,"height":360},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/jqN.vTpHE33ulSAnjnKCrw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD05MDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/3877a14729dc5f1fce3a3e099213b3e8","width":1200,"height":450}},"lazy":false},{"type":"text","content":"MALAKOFF, France, January 29, 2026--(BUSINESS WIRE)--Regulatory News:","length":69,"tagName":"p"},{"type":"text","content":"THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing Sonovein®, a robotic platform for non-invasive High-Intensity Focused Ultrasound (HIFU) varicose vein treatment, provides an update on its key achievements in 2025 and has built strong foundations for 2026.","length":286,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Clinical efficacy validated through the FDA pivotal study and major new scientific publications","length":95,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Three key regulatory milestones achieved in the United States, Europe and China","length":79,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":""Pay per Use" (PPU) business model showing traction and ready to scale up","length":83,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":257,"olType":false},{"type":"text","content":"Martin Deterre, Theraclion’s CEO, states, "In 2025, we proved that our technology is no longer a promise but a clinical and commercial reality. Theraclion offers a genuine non-invasive, robotic technological breakthrough, providing access to the surgery of tomorrow. Strong regulatory, industrial and commercial foundations have been built, ensuring Sonovein’s® ramp-up in the years ahead. Commercial momentum has taken hold, with stronger organization, several dozen new centers added to our prospect list, and several new contracts signed in recent weeks. We are ready to c...

More updates from Theraclion Sa